Introduction
Tumours containing activating epidermal growth factor receptor mutations (EGFRm) (e.g. deletion in exon 19 or an L858R point mutation) account for about 20% of advanced non small cell lung cancer (NSCLC) (1) . Although these mutations also sensitise EGFR to inhibition by the established tyrosine kinase inhibitor (TKI) therapies erlotinib and gefitinib (2) , almost all tumours will develop acquired resistance to these TKIs within 9-15 months (3, 4) . In aproximately 60% of cases, this acquired resistance is associated with an additional T790M mutation in EGFR (5-7). As there are currently no treatments approved for patients with these tumours (8, 9) new EGFR TKIs such as AZD9291, WZ4002 and CO-1686 are being developed which inhibit both EGFRm and T790M mutations in preclinical models (10-12). AZD9291 and CO-1686 have also shown promising Phase 1 activity in patients with T790M advanced NSCLC who have progressed while on prior therapy with an EGFR-TKI (10, 11). These new TKIs may also provide treatment options in the TKI-naive setting for patients with advanced EGFRm NSCLC. However, despite the potential improvements from therapy with these TKIs, experience with targeted agents suggest that resistance to these drugs may also emerge and potentially limit their effectiveness. Therefore identification of resistance mechanisms is important to drive new therapeutic strategies for treating drug resistance in patients.
In vitro, EGFRm cells chronically exposed to escalating doses of gefitinib or erlotinib acquire clinically relevant resistance mechanisms (13, 14) , and subsequent studies tumours are likely to derive acquired resistance through multiple mechanisms, we postulated that it may be better to take a population approach to understanding the diversity and interplay of resistance mechanisms. We studied multiple cell populations resistant to gefitinib, afatinib, WZ4002 or AZD9291 to identify predominant mechanisms of resistance and to investigate signaling pathways activated by various resistance mechanisms. Eberlein et al. Illumina; Ion Torrent PGM platform, Life Technologies and by Sanger di-deoxy sequencing. Comparative genomic hybridization was performed using SurePrint G3 Human CGH microarrays, Agilent Technologies (Santa Clara, USA). Sequence data processing, mutation detection and gene copy number assessment were carried out as described in Supplementary Material. Data is accessible in NCBI's Sequence Read Archive accession number SRP044079 and NCBI's Gene Expression Omnibus (GEO) accession number GSE59239.
Transgenic mouse studies and MRI
In vivo experiments were carried out as previously described using both EGFR L858R+T790M and EGFR L858R transgenic models (10) 
Results

Generation of EGFR mutant cell populations resistant to AZD9291 and other
EGFR TKIs
To carry out a broad investigation into acquired resistance to EGFR inhibitors, we generated in parallel multiple EGFRm (PC9; Ex19del. chosen as a validated cell line for modeling EGFR inhibitor resistance (26)) and EGFRm/T790M (PC9 derivatives and NCI-H1975; L858R/ T790M) cell populations with induced resistance to gefitinib, afatinib, WZ4002 or AZD9291, using either a dose escalation method or by culturing the cells in a single dose of AZD9291 (Supplementary Table S1 ).
Resistance to AZD9291 and other EGFR TKIs is often associated with increased sensitivity to MEK inhibition
To investigate whether the survival of resistant populations was through activation of alternative signaling pathways that circumvent EGFR dependency, we used a diverse panel of small molecule inhibitors representing key signaling pathways or emerging resistance mechanisms (Supplementary Table S2 ). The ability of each agent, in the presence of originating EGFR TKI, to inhibit cell growth was measured using an in vitro phenotypic assay, and IC 50 values determined following 72 hours treatment ( Table 1; Supplementary Table S3 ). It was striking that 13 of 28 PC9 resistant populations and 2 of 4 NCI-H1975 resistant populations were greater than 5 times more sensitive to the MEK inhibitor selumetinib in combination with the originating EGFR inhibitor, when compared to the corresponding parental cells treated with selumetinib.
We therefore focused subsequent studies on understanding mechanisms of selumetinib sensitivity in these populations. To confirm that increased selumetinib sensitivity was related to RAS-MAPK pathway inhibition, phosphorylation levels of ERK1/2 and MEK1/2 were analysed by immunoblotting PC9 parental and resistant populations grown in the presence of EGFR inhibitor and treated with increasing concentrations of selumetinib. Resistance to selumetinib in the PC9, PC9 GR_4 and PC9 GR_5 cells was associated with a strong induction of phosphorylated MEK and weaker inhibition of ERK phosphorylation when compared to the effects of selumetinib in the sensitive cell populations, PC9 GR_2 and PC9 AZDR_4 (Fig 1A) . The dependency of EGFR resistant cell populations on RAS-MAPK activity was further analysed using PC9 WZR_1 cells which showed > 5 fold increased sensitivity to selumetinib ( Table 1) .
Consistent with PC9 GR_2 and AZDR_4 populations, WZR_1 cells maintained in presence of WZ4002 demonstrated expected inhibition of phosphorylated EGFR, and phosphorylated ERK (Fig. 1Bi ) and growth inhibition (Fig. 1C) were highly sensitive to selumetinib treatment. In contrast, WZR_1 cells that had been cultured in the absence of WZ4002 displayed an EGFR and selumetinib ERK sensitivity profile similar to that seen in PC9 parental cells namely weak inhibition of ERK phosphorylation and strong induction of pMEK (Fig. 1A, Fig. 1Bii) , with associated growth inhibition refractory to selumetinib (Fig. 1C) . The strong increase in levels of phosphorylated MEK1/2 in response to selumetinib treatment in the resistant compared to the sensitive populations (Fig. 1A, Fig 1Bi) suggests a difference in pathway activity upstream of MEK between sensitive and resistant populations in response to relief of negative feedback loops upon MEK inhibition. In order to investigate the molecular drivers of EGFR TKI resistance we analysed DNA samples prepared from parental and a selection of 32 resistant populations (Supplementary Table S1 ) for the presence of gene mutations and/or copy number changes across a panel of cancer associated genes using multiple assay platforms.
Comparison of genetic alterations across multiple populations of EGFRm or
The genetic modifications detected and associated allele frequencies for PC9 and NCI-H1975 populations are summarised in Table 1 and Supplementary Fig. S1 .
Each mutation detected was confirmed across at least 2 different assay platforms (Supplementary Table S4 ).
Across the PC9 populations, 7/8 gefitinib and 2/3 afatinib resistant populations had detectable T790M mutations, whereas none of the populations resistant to the WZ4002 or AZD9291 had acquired a detectable T790M mutation ( Table 1) . The T790M gefitinib resistant populations mostly showed sensitivity to AZD9291, with dose response curves indicating almost all cells in populations PC9 GR_4, 6 and 7 were sensitive to AZD9291 (Supplementary Fig. S2Ai ). However, less than 50% of cells in populations PC9 GR_1 (T790M, KRAS gain 5.43 fold), PC9 GR_3 (T790M) and PC9 GR_5 (T790M) were sensitive to growth inhibition by AZD9291 (Supplementary Fig. S2Aii ), suggesting these populations contained heterogenous resistant mechanisms. The IC 50 values across all AZD9291 sensitive cells were similar (Supplementary Fig S2B) . Although T790M was detected within the PC9 GR_8 (T790M, KRAS gain 7.06 fold) population, these cells showed no sensitivity to AZD9291 (Supplementary Fig. S2Aiii) Supplementary Fig. S3 ). This novel NRAS mutation occurs within the functional domain at a sequence position parallel to somatic mutations observed in both KRAS (27) and HRAS (28). We also identified functionally activating NRAS G12V and G12R mutations in 2 different AZD9291-resistant PC9 populations ( Table 1) . This is the first identification of G12V NRAS in the context of NSCLC. In addition to gene mutations, copy number gains of MAPK1, CRKL, NRAS and KRAS were detected across the resistant populations (Table 1) , with the gain of NRAS and KRAS resulting in increased protein levels (Supplementary Fig. S4 ). Of particular interest KRAS gain was observed in the T790M PC9_GR_1 population that was partially sensitive to AZD9291 ( in populations PC9 GR1_AZDR_1, 3 and 4 T790M was no longer detectable in PC9 GR1_AZDR_2 cells.
Modifications of RAS genes can drive resistance to EGFR inhibition
As NRAS mutations were detected in 7 of the resistant populations, and frequently associated with selumetinib sensitivity, it's role in resistance was further investigated.
Basal levels of active NRAS were lower in parental PC9 cells compared to resistant PC9 populations in which E63K, G12V, ( Fig. 2A) Fig. S5C ). Knockdown of NRAS in cell populations with 3 separate siRNAs, but not KRAS, for 72 hours resulted in a significant decrease in phosphorylated ERK in the resistant populations harboring NRAS mutations, but to a lesser extent in the PC9 parental cells (Fig. 2C) .
Moreover, knockdown of NRAS but not KRAS was associated with inhibition of proliferation only in the NRAS mutant populations (Fig. 2D) . These data indicate that activating NRAS mutations including the novel E63K NRAS are sufficient to drive As KRAS gain was detected within 8 resistant populations (Table 1) , we determined whether this could similarly drive resistance. Knockdown of KRAS in PC9 parental cells had no effect on cell growth or levels of phosphorylated ERK (Fig. 2C) , whereas KRAS knockdown in PC9 AR_1 (KRAS gain 24.6 fold), in the presence of afatinib, caused a significant decrease in both phosphorylated ERK levels after 48 hours ( Fig. 3A) and proliferation over 72 hours (Fig. 3B) . Interestingly, knockdown of KRAS in the PC9 GR_1 (T790M and KRAS gain 5.43 fold) population, had no effect on cell proliferation alone or when treated in combination with gefitinib ( Fig.   3C ). However a significant decrease in cell growth was observed when KRAS knockdown was combined with AZD9291 treatment (Fig. 3C) . Consistent with this, knockdown of KRAS in the presence of AZD9291 resulted in complete inhibition of phosphorylated ERK, but not in case of gefitinib (Fig. 3D ). These observations suggest that KRAS and T790M are both important for driving resistance in the PC9 GR_1 population.
Interestingly, we noted that a 2.64 fold gain of KRAS, as detected in WZR_3 cells, was associated with increased sensitivity to selumetinib, but cell populations with KRAS gains of between 4.44 and 24.6 fold were insensitive to selumetinib ( Table 1) , suggesting a threshold effect of KRAS expression. Indeed, partial knockdown of KRAS for 48 hours in AR_1 cells (KRAS gain 24.6 fold) with afatinib resensitised them to selumetinib inhibition as revealed by decreased phosphorylated ERK, FRA1 and p90RSK levels compared to cells similarly treated with control siRNA (Fig 3E) . Moreover partial knockdown of KRAS followed by treatment with selumetinib resulted in significantly greater inhibition of cell growth compared to cells treated with control siRNA (Fig. 3G) . In contrast, no significant increase in inhibition of MAPK pathway or cell growth was observed with partial knockdown of KRAS followed by selumetinib treatment in WZR_3 cells (KRAS gain 2.64 fold) cultured in the presence of WZ4002 (Fig. 3F, 3H 
In vitro a combination of AZD9291 with selumetinib delays or prevents resistance emerging in EGFRm and EGFRm/T790M cells
Since the data had indicated that RAS-MAPK activation was a frequent mechanism of AZD9291 and other EGFR TKI resistance, we tested whether treatment with a combination of AZD9291 and selumetinib could delay or prevent the emergence of resistance in these settings. AZD9291, no resistant cells were observed over a similar time with a combination of AZD9291 and selumetinib (Fig. 4A) . To investigate the combination in the EGFRm/T790M setting, NCI-H1975 cells were treated with 160nM AZD9291 or 100nM selumetinib alone or in combination. Treatment with 100nM selumetinib alone did not inhibit proliferation of NCI-H1975 cells (Fig. 4B) . Treatment with AZD9291 initially slowed the rate of proliferation, however a small resistant population had emerged following 17 days of treatment (Fig. 4B) . Treatment with a combination of AZD9291 and selumetinib significantly delayed outgrowth of resistant cells compared to AZD9291 alone (Fig. 4B) . Similarly a combination of AZD9291 with selumetinib prevented emergence of resistance in 2 other cell lines, HCC827 (EGFR Ex19del) and NCI-H820 (EGFR Ex19del/T790M+/MET amp ) ( Supplementary Fig. S6A , B).
To further explore the EGFRm/T790M setting, PC9 GR_1 cells (T790M and KRAS gain) were treated with a combination of AZD9291 and selumetinib. Following treatment an increase in pro-apoptotic markers, cleaved PARP and BIM, and a decrease in anti-apoptotic BclxL was observed together with a more profound effect on phosphorylated ERK levels than either agent alone (Fig. 4C) . Moreover the combined effect of inhibition of ERK signaling and apoptotic pathway was associated with a greater decrease in cell number over 12 days compared to either inhibitor alone (Fig. 4D) . Although combination of selumetinib and AZD9291 did not increase apoptotic markers in NCI-H1975 (Fig. 4E) , a profound anti-proliferative effect was observed following 12 days treatment with the combination compared to each agent alone (Fig. 4F ). Overall these in vitro studies indicated that combining AZD9291 with selumetinib lead to more profound mechanistic and phenotypic inhibition of cells. 
In vivo a combination of AZD9291 with selumetinib caused regression of AZD9291 resistant tumours in transgenic models
Finally, we tested the concept that MEK pathway inhibition could circumvent resistance to AZD9291 using in vivo mouse tumour models that develop lung adenocarcinomas driven by EGFR L858R + T790M or EGFR L858R (29) and are highly sensitive to inhibition by AZD9291 (10). Three animals with EGFR L858R + T790M transgenic tumours were chronically treated with 5 mg/kg/day AZD9291 and showed initial tumour regression followed by progressive disease after 3 months treatment (Fig. 5A ). Animals were subsequently treated with AZD9291 in combination with 5 mg/kg twice daily of selumetinib. Remarkably, resistant tumours in 3/6 animals showed a profound response to the combination, showing strong regression after 1-2 months of combination treatment (Fig. 5A) . Tumour regression was not observed when tumour-bearing EGFR L858R + T790M mice were treated with selumetinib alone for 1-2 weeks (Fig. 5B) . Similarly, an animal bearing an EGFR L858R tumour showed progression after 3 months of AZD9291 treatment, which regressed following combination of AZD9291 with selumetinib (Fig. 5C) . These data provide compelling in vivo evidence to support RAS-MAPK signaling dependency as an important resistance mechanism to AZD9291.
Basal levels of RAS-MAPK pathway components do not predict MEK inhibitor sensitivity across resistant populations
We also explored whether the activity status of RAS-MAPK pathway could identify tumours that would benefit from combination of EGFR TKI with selumetinib. Supplementary Fig. S4 ). Consistent with this data, analysis of phosphorylated and total protein levels using a Reverse Phase Protein Array (RPPA), showed basal levels of phosphorylated ERK were not indicative of selumetinib sensitivity (Supplementary Table S1; Supplementary Table S5 ). In conjunction with this, sensitivity to MEK inhibition was not consistently correlated with levels of other phosphorylated or total proteins known to be involved in RAS-MAPK signaling (Supplementary Table S5 ). 
Discussion
Significant advances in our understanding of acquired resistance to EGFR targeted drugs in EGFRm NSCLC, including but not limited to identification of T790M, MET or HER2 amplification and PIK3CA mutants (6), is helping towards the development of new rational treatment strategies to potentially prolong patient benefit such as AZD9291 and CO-1686 which target T790M. However, a large proportion of EGFR inhibitor acquired resistance remains unexplained, and it is anticipated that cells will also find alternative mechanisms to circumvent inhibition by new agents such as AZD9291 and CO-1686.
We have used a novel approach by directly comparing resistance mechanisms across 32 populations with acquired resistance to different EGFR TKIs, and provide the first pre-clinical in-depth analysis of AZD9291 acquired resistance. We took a population approach to try to better emulate the heterogeneity of resistance that occurs in advanced tumours due to competing pressures on both selection of existing clones and gain of new alterations.
A key finding is identification of certain NRAS mutations or NRAS gain as the most frequently detected genetic modifications able to drive resistance to AZD9291.
Although previous in vitro data has similarly identified an NRAS Q61K mutation in acquired resistance to gefitinib or erlotinib (24, 30), this is the first report of an NRAS activating mutation conferring acquired resistance to other EGFR inhibitors such as AZD9291. Furthermore this is the first report of the novel NRAS E63K mutation, and together with NRAS G12V, the first report of these NRAS mutations associated with EGFRm NSCLC. The high incidence of NRAS modifications was somewhat surprising in light of recent clinical data in which common NRAS mutations were not detected in lung cancers with acquired resistance to gefitinib or erlotinib (7, 24). with new EGFR TKIs to overcome such acquired resistance mechanisms or potentially in earlier treatment as part of prevention strategies. Interestingly, our data support that this combination may provide benefit in both T790M and EGFRm TKInaïve settings.
In addition to increased sensitivity to selumetinib across a number of the resistant populations we also observed increased sensitivity to the Aurora kinase B inhibitor AZD1152-HQPA, in combination with AZD9291, in all of the AZD9291 resistant NCI- Table S3 ). This is consistent with recent reports (37) and is worthy of further investigation.
H1975 populations compared to the parental cells (Supplementary
Overall, the emerging pre-clinical evidence presented here supports a picture whereby during chronic exposure to AZD9291, competing selection pressures are likely to influence which clones within a heterogeneous population ultimately become dominant. This could also involve T790M clones becoming less prevalent within a tumour as other resistance clones become more dominant. Moreover, data from ourselves and others provide a compelling rationale for combining inhibitors of the RAS-MAPK signaling such as selumetinib with AZD9291 across EGFRm settings in NSCLC, to tackle RAS-MAPK as a potentially important escape mechanism within such clones. A key challenge will be to develop effective patient selection strategies to identify those patients who may benefit from such a combination. Emerging data suggest multiple genetic and non-genetic alterations, including certain NRAS modifications reported here, could occur that converge on activating the RAS-MAPK pathway, and therefore it is possible that a broad biomarker platform will need to be established. It is important that measuring basal phosphorylation levels of ERK is unlikely to be sufficient to determine dependence on RAS-MAPK signaling or Tables   Table 1. IC represents cell lines which are at least 5 fold more sensitive to selumetinib than in the relevant parental cell line.
represents cell lines which are at least 5 fold less sensitive to AZD9291 than in the relevant parental cell line. NTC  siNRAS_1  siNRAS_2  siNRAS_3  siKRAS  NTC  siNRAS_1  siNRAS_2  siNRAS_3  siKRAS  NTC  NTC  siNRAS_1  siNRAS_2  siNRAS_3  siKRAS  NTC  NTC  siNRAS_1  siNRAS_2  siNRAS_3 
